The relation between fibroblast growth factor 23 level and anemia in chronic kidney disease patients. | ||||
| Minia Journal of Medical Research | ||||
| Volume 31, Issue 4, October 2020, Page 33-38 PDF (228.94 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2022.217059 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Yousef I. Mousa1; Mahmoud H. Kheder2; Hend M. Moenes3; Maha K. Shehata2 | ||||
| 1Department of Internal Medicine, Faculty of Medicine, Minia University, Egypt. | ||||
| 2Department of Internal Medicine, Faculty of Medicine, Minia University, Egypt | ||||
| 3department of Clinical Pathology Faculty of Medicine, Minia University, Egypt. | ||||
| Abstract | ||||
| Background: Anemia is commonly observed in the course of chronic kidney disease (CKD) and it is associated with diminishing the quality of a patient’s life. It also increases morbidity and mortality and CKD progression rate, so it is critical to continue investigations that help explain risk factors involved in the development of anemia in CKD. FGF23 is a promising biomarker of adverse outcomes in patients with CKD. Several studies have suggested a possible association between FGF23 and anemia in these patients. The aim of the current study was to detect level of FGF23 in CKD patients and clarify the relation between of FGF23 level and anemia in CKD patients. Subjects and Methods: Subjects: This case - control study was conducted on 90 subjects at the nephrology department of Minia University Hospital through the period from March 2019 to November 2019 selected and divided into three groups containing both control and patients groups. Group І included 30 patients with chronic kidney disease, not on hemodialysis, Group ІI included 30 patients with chronic kidney disease on Hemodialysis and both are with anemia. Group ІII included 30 individuals who are the healthy group. Exclusion criteria: Pregnancy, liver cirrhosis, Polycystic kidney disease, Renal cancer, Recent chemotherapy or immunosuppressive therapy, New York Heart Association class 3 or 4 heart failure, Multiple myeloma, Overt gastrointestinal diseases such as untreated gastric cancer and ulcers, Abnormalities of the white blood cell count and differential or platelet count. Laboratory methods: A)Blood sampling protocol: 6 ml of blood was withdrawn by sterile venipuncture and before dialysis session in the second group, left to be clotted then centrifuged and the separated serum was divided into liquates. One was designated for the immediate assessment of routine chemistry, The rest of serum was stored at -5 c for subsequent assay of specific labs. B) Routine laboratory Investigations: Using the commercially available kits, all patients underwent full laboratory investigation including Complete blood count (CBC) and Renal function tests (serum urea and creatinine). C) Specific investigation: eGFR, HS-CRP, Iron profile (serum Iron, Ferritin, TIBC), calcium (Ca), phosphate (P), intact (i)-PTH level and i-FGF23 level. D) Imaging studies: Abdominal ultrasound was performed by General Electric ultrasound and transducer with a frequency of 3.5 megahertz (MHz), USA. Statistical analysis: Statistical analysis was conducted using the Statistical Package for Social Sciences (SPSS software version 25). Results: Elevated FGF23 inversely correlated with iron deficiency anemia in patients with CKD dialysis patients of statistical significance (P=0.012). Conclusion: FGF23 levels in CKD are higher than levels observed in healthy patients, elevated FGF23 inversely correlated with iron deficiency anemia in patients with CKD patients, and with high sensitivity and specificity of FGF23 as a promising marker for prediction of disease progression. | ||||
| Keywords | ||||
| CKD; Anemia; FGF23; Hemodialysis. All authors have no conflict of interest | ||||
|
Statistics Article View: 79 PDF Download: 294 |
||||
